Johnson & Johnson - Risperdal, Invega, Natrecor, Levaquin, Procrit

Company: Johnson & Johnson
Settlement amount: Reportedly between $1.6 billion and $2.2 billion
Drugs: Risperdal, Invega, Natrecor, Levaquin, Procrit, according to press reports
Year: 2012

You might call Johnson and Johnson's ($JNJ) Risperdal settlement an omnibus deal. It is expected to cover federal probes about off-label Risperdal marketing, state claims of Medicaid fraud (also related to Risperdal), kickback allegations involving the nursing home pharmacy provider Omnicare and several other drugs besides Risperdal. It would also settle litigation over marketing practices involving Invega, another antipsychotic, and Natrecor, a congestive heart failure treatment. The company had already pleaded guilty to misbranding Natrecor and agreed to pay an $85 million fine.

What it doesn't cover, according to media sources: Lawsuits filed by several states that either have their own individual deals or jury verdicts, or are holding out for one or the other. Texas, for instance, which settled its off-label marketing claims against J&J for $158 million. Arkansas, where a jury found the company guilty of fraudulently marketing Risperdal--and a judge ordered the company to pay a $1.2 billion penalty. (That award is under appeal.)

J&J's settlement would wrap up some 8 years of government investigations and whistleblower lawsuits. From 2003 to 2010, Risperdal brought in more than $24 billion worldwide; in the U.S. alone, the drug ginned up $20 billion before it lost patent protection in 2007. Much of that revenue came from off-label sales, investigators have said.

Read More:
Johnson & Johnson - Risperdal, Invega, Natrecor, Levaquin, Procrit